FFO
REGN icon

Fortitude Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Fortitude Family Office’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
28
+3
+12% +$2.04K ﹤0.01% 571
2026
Q1 		$19.3K Buy
25
+14
+127% +$10.7K ﹤0.01% 439
2025
Q4 		$8.49K Sell
11
-4
-27% -$2.72K ﹤0.01% 632
2025
Q3 		$8.43K Sell
15
-3
-17% -$1.7K ﹤0.01% 626
2025
Q2 		$9.45K Sell
18
-36
-67% -$20.1K ﹤0.01% 577
2025
Q1 		$34.2K Hold
54
– – 0.01% 290
2024
Q4 		$38.5K Sell
54
-2
-4% -$1.68K 0.01% 304
2024
Q3 		$58.9K Hold
56
– – 0.02% 218
2024
Q2 		$58.9K Buy
56
+21
+60% +$20.4K 0.03% 156
2024
Q1 		$33.7K Hold
35
– – 0.02% 199
2023
Q4 		$30.7K Buy
+35
New +$28.8K 0.02% 230

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fortitude Family Office's REGN Position: Q2 2026 in Review

Fortitude Family Office increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, buying an estimated $2.04K and bringing the position to 28 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #571.

Fortitude Family Office first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $58.9K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Fortitude Family Office held 28 shares of Regeneron Pharmaceuticals worth $17.5K as of Q2 2026.
  • Fortitude Family Office bought 3 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.04K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #571 holding.
  • Fortitude Family Office first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Fortitude Family Office's Regeneron Pharmaceuticals position peaked at $58.9K in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.